Evidence map›Paper›PMID 41208232›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

LMO7 Suppresses Tumor-Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1.

Mengkai Li, Tao Wang, Yuwen Zhong, Zhiming Wang, Wei Li, Zejian Wang, Xinyi Yang, Yu Qiao, Jianfeng Xiang, Wei Gu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mengkai LiShanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, P. R. China.
Tao WangDepartment of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200240, P. R. China.
Yuwen ZhongShanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, P. R. China.
Zhiming WangShanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, P. R. China.
Wei LiCore Facility and Technical Service Center, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, P. R. China.
Zejian WangCore Facility and Technical Service Center, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, P. R. China.
Xinyi YangShanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, P. R. China.
Yu QiaoAnhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical University, Bengbu Medical University, Bengbu, Anhui, 233030, P. R. China.
Jianfeng XiangDepartment of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200240, P. R. China.
Wei GuAnhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical University, Bengbu Medical University, Bengbu, Anhui, 233030, P. R. China.
Zishu WangAnhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical University, Bengbu Medical University, Bengbu, Anhui, 233030, P. R. China.
Lei SunShanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, P. R. China.ORCID https://orcid.org/0000-0002-8288-4289
Feng QianShanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, P. R. China.

Funding

Anhui Province Key Laboratory of Translational Cancer Research KFKT202302Anhui Province Scientific Research Compilation Plan Project 2022AH040214Anhui Province Translational Special Project for Clinical Medical Research 202204295107020038Anhui Provincial Health Science and Technology Project AHWJ2024Aa40012National Key Research and Development Program of China 2023YFA0913700National Natural Science Foundation of China 82173821National Natural Science Foundation of China 82273934National Natural Science Foundation of China 82373875National Natural Science Foundation of China 82473928National Natural Science Foundation of China 82574414Shanghai Jiao Tong University Decision Consulting Project-Experimental Technology Project JCZXSJB2022-28
6 · The paper itself

Abstract

Tumor-associated macrophages (TAMs) are one of the most abundant immune cells in solid tumors and play a critical role in tumor progression. This study found that the expression of LIM domain-only protein 7 (LMO7) in TAMs is associated with poor patient survival. LMO7 deficiency significantly inhibited tumor growth and increased the accumulation of antitumor TAMs and CD8

Indexed as

LIM Domain ProteinsLow Density Lipoprotein Receptor-Related Protein-1PhagocytosisTranscription FactorsTumor-Associated MacrophagesAnimalsCell Line, TumorHumansMiceLIM Domain ProteinsLMO7 protein, humanLow Density Lipoprotein Receptor-Related Protein-1LRP1 protein, humanTranscription FactorsLMO7LRP1phagocytosistumor‐associated macrophagetumor immune microenvironment

Identifiers

PMID41208232
PMCPMC13292253

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.